Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2007 1
2008 1
2009 2
2011 4
2012 7
2013 9
2014 15
2015 19
2016 9
2017 9
2018 14
2019 5
2020 4
2021 2
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Insights in Dolutegravir-resistance pathways.
Mesplede T, Gantner P. Mesplede T, et al. Clin Infect Dis. 2024 Mar 11:ciae127. doi: 10.1093/cid/ciae127. Online ahead of print. Clin Infect Dis. 2024. PMID: 38462992 No abstract available.
Might dolutegravir be part of a functional cure for HIV?
Wainberg MA, Han YS, Mesplède T. Wainberg MA, et al. Among authors: mesplede t. Can J Microbiol. 2016 May;62(5):375-82. doi: 10.1139/cjm-2015-0725. Epub 2016 Jan 27. Can J Microbiol. 2016. PMID: 27031127 Free article. Review.
Evolution of HIV integrase resistance mutations.
Quashie PK, Mesplède T, Wainberg MA. Quashie PK, et al. Among authors: mesplede t. Curr Opin Infect Dis. 2013 Feb;26(1):43-9. doi: 10.1097/QCO.0b013e32835ba81c. Curr Opin Infect Dis. 2013. PMID: 23242340 Review.
The latest evidence for possible HIV-1 curative strategies.
Pham HT, Mesplède T. Pham HT, et al. Among authors: mesplede t. Drugs Context. 2018 Feb 21;7:212522. doi: 10.7573/dic.212522. eCollection 2018. Drugs Context. 2018. PMID: 29497452 Free PMC article. Review.
Resistance to HIV integrase inhibitors.
Mesplède T, Quashie PK, Wainberg MA. Mesplède T, et al. Curr Opin HIV AIDS. 2012 Sep;7(5):401-8. doi: 10.1097/COH.0b013e328356db89. Curr Opin HIV AIDS. 2012. PMID: 22789986 Review.
Reply to Achieng and Riedel.
Pham HT, Goring ME, Mesplède T. Pham HT, et al. Among authors: mesplede t. J Infect Dis. 2019 Jan 1;219(1):167-169. doi: 10.1093/infdis/jiy437. J Infect Dis. 2019. PMID: 30165488 No abstract available.
Reply to Darcis and Berkhout.
Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA. Wijting IEA, et al. Among authors: mesplede t. J Infect Dis. 2018 Nov 5;218(12):2020-2021. doi: 10.1093/infdis/jiy475. J Infect Dis. 2018. PMID: 30085047 No abstract available.
Investigational drugs for HIV: trends, opportunities and key players.
Overmars RJ, Krullaars Z, Mesplède T. Overmars RJ, et al. Among authors: mesplede t. Expert Opin Investig Drugs. 2023 Feb;32(2):127-139. doi: 10.1080/13543784.2023.2178415. Epub 2023 Feb 15. Expert Opin Investig Drugs. 2023. PMID: 36751107 Review.
104 results